SCCRO inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the SCCRO (Sensitive to Cell Death Regulated by Oxidation) protein, also known as DCUN1D1. SCCRO is a crucial component of the NEDD8 conjugation pathway, a process that modulates the activity of cullin-RING ligases (CRLs), which are involved in protein ubiquitination and degradation. By mediating the neddylation of cullin proteins, SCCRO plays a pivotal role in maintaining the ubiquitin-proteasome system's functionality, ensuring that cellular proteins are properly tagged for degradation or stabilization. SCCRO inhibitors are designed to disrupt the activity of SCCRO, interfering with the neddylation process and ultimately impairing the regulation of CRLs. This interference can lead to alterations in the ubiquitination and degradation of various proteins that are crucial for cellular homeostasis.
The inhibition of SCCRO has broader implications in regulating cellular pathways, particularly in pathways related to protein degradation, cell growth, and response to oxidative stress. By inhibiting SCCRO activity, these inhibitors can affect the proteasomal degradation of key signaling molecules, such as transcription factors, enzymes, and other regulatory proteins that are essential for cell cycle progression and cellular stress responses. Furthermore, SCCRO inhibitors can influence the cellular redox state by modifying the turnover rates of proteins involved in maintaining oxidative balance. This interference can lead to a shift in cellular redox potential, potentially impacting metabolic pathways that rely on redox-sensitive enzymes. The ability of SCCRO inhibitors to modulate such intricate cellular processes highlights their significance as valuable tools for studying protein degradation pathways and the regulation of cellular redox homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin might downregulate SCCRO by inhibiting the activation of NF-κB, which is known to enhance the transcription of various oncogenes, potentially including SCCRO. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol could decrease SCCRO levels by stimulating SIRT1, which in turn deacetylates specific transcription factors that trigger SCCRO gene transcription. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin is proposed to reduce SCCRO transcription by suppressing the activity of PI3K/Akt pathway enzymes, which are critical for the transcriptional activation of many oncogenes. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
DL-Sulforaphane might attenuate SCCRO expression by inducing hypermethylation of DNA within the promoter region of the SCCRO gene, thereby hindering its transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid could suppress SCCRO expression by binding to retinoic acid receptors, which may interact with SCCRO gene promoters to inhibit its transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may decrease SCCRO expression by causing hypomethylation of the SCCRO gene promoter, thereby silencing its transcriptional activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid is thought to reduce SCCRO gene expression by altering the acetylation status of histones at the SCCRO gene locus, leading to a closed chromatin configuration that is less transcriptionally active. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram could lead to a reduction in SCCRO expression by inhibiting the proteasomal pathway, which might increase the stability of transcriptional repressors of SCCRO. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib may contribute to decreased SCCRO levels by inhibiting the proteasome, leading to the accumulation of cellular proteins that repress oncogene transcription. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide could inhibit SCCRO expression by preventing the binding of specific transcription factors to the SCCRO promoter or by inducing chromatin modifications that reduce gene accessibility. | ||||||